Mark is a keen champion of innovation in the context of collaborative delivery models and he is particularly interested in transformational change in the infrastructure industry (including: digital transformation, connected digital twins, Smart Infrastructure, low-carbon sustainable solutions, platform-based delivery and design for manufacture and assembly).
As Mott MacDonald’s Chief Technical Officer, Mark is accountable to the Executive Board for technical excellence across the Group. As the Chair of Centre for Digital Built Britain’s Digital Framework Task Group, Mark is leading the National Digital Twin Programme.
Mark is the Digital Transformation workstream lead on “Project 13” for the Infrastructure Client Group, which represents the UK’s major infrastructure client organisations and he was the Lead Author of the Infrastructure Carbon Review, published by HM Treasury.
Dan THOMAS has been the Financial Times’ Executive News Editor since August 2018. Dan was previously the FT’s deputy companies editor and telecoms editor.
Prior to that, he worked as the FT’s property correspondent. He has also reported for FT Money and FT Weekend’s personal finance supplement. Prior to joining the FT in March 2007, he was an assistant editor for Property Week.
The global Drug Product Design group is responsible for all small molecule Drug Product activities from molecular design in Research through to global registration and supporting the commercial launch. Brian Henry also leads the UK Medicinal Sciences group and represents Pfizer on the EFPIA and ABPI Innovation boards, the Medicines Manufacture Innovation Partnership Board and is Professor of Pharmaceutics at the University of Nottingham.
Digital design and the predictive sciences are key components of Pfizer's drug product acceleration strategy by driving speed, reducing costs and development scale-up risk reduction. Digital twin approaches are becoming increasingly important in delivering this strategy from modelling molecular interactions at the protein level through to resolving tablet manufacturing scale up risks.